

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	5353928
<b>Application Number:</b>	09708352
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	1597
<b>Title of Invention:</b>	Vaccines for Mycoplasma bovis and methods of use
<b>First Named Inventor/Applicant Name:</b>	Joan D. Leonard
<b>Correspondence Address:</b>	<p>KENYON &amp; KENYON - ONE BROADWAY - NEW YORK NY 10004 US 212 425 7200 -</p>
<b>Filer:</b>	Kevin Todd Godlewski/Erica Brauer
<b>Filer Authorized By:</b>	Kevin Todd Godlewski
<b>Attorney Docket Number:</b>	02108.0001U2
<b>Receipt Date:</b>	18-MAY-2009
<b>Filing Date:</b>	08-NOV-2000
<b>Time Stamp:</b>	16:58:43
<b>Application Type:</b>	Utility under 35 USC 111(a)

### **Payment information:**

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$1080

RAM confirmation Number	3242
Deposit Account	110600
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)  
 Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)  
 Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)  
 Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)  
 Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/Message Digest	Multi Part /.zip	Pages (if appl.)
1	Reply Brief Filed	12780transmittal.pdf	74673 38084f1397b51824104f76575fb1b0681c58 c2ee	no	1

### Warnings:

### Information:

2	Reply Brief Filed	12780replybrief.pdf	163432 c39eb3f1dd359e85880082608928c6f94f ebcf	no	12
---	-------------------	---------------------	--	----	----

### Warnings:

### Information:

3	Request for Oral Hearing	12780request.pdf	295983 5998634bc23002018e21bec73b2ce903755 aec11	no	2
---	--------------------------	------------------	--	----	---

### Warnings:

### Information:

4	Fee Worksheet (PTO-875)	fee-info.pdf	30390 355244ddcb892e8118a20e009412ea92e85 09a35	no	2
---	-------------------------	--------------	---	----	---

### Warnings:

### Information:

<b>Total Files Size (in bytes):</b>	564478
-------------------------------------	--------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.